Jefferies reiterates Legend Biotech stock rating on Carvykti sales By Investing.com

Jefferies reiterated a Buy and $69 price target on Legend Biotech while the stock trades at $19.41, implying >250% upside to the target. Jefferies projects Carvykti worldwide net sales of $2.9B in 2026, LTM revenue of $909M (+75% YoY), and expects the franchise to breakeven in 2025; the firm also introduced 2028 forecasts and plans to present in vivo CAR‑T human data in H2 2026. Q4 2025 EPS was $0.01 in line with estimates, while revenue was $306M versus $310.71M expected (slight miss).

Analysis

The immediate market implication is idiosyncratic to LEGN’s execution pathway rather than a broad biotech re-rate: positive commercial momentum narrows the path-dependency from clinical binary outcomes to operational capacity (manufacturing, fill/finish, vial-to-patient throughput). That shifts second-order winners to large, diversified CDMOs and reagent suppliers who can absorb step-ups in viral-vector and cell-processing demand; conversely, pure-play small CDMOs and niche biotechs without scale are at risk of losing margin share and capacity contracts.

Key catalysts and tail risks separate into timing buckets. Near-term (days–months) sensitivity will come from quarterly sales cadence and any incremental guidance; medium-term (6–18 months) hinges on manufacturing scale metrics and payer contracting cadence; binary clinical/regulatory catalysts (in‑vivo human data) sit H2 2026 and could either re-rate the equity materially or expose safety/efficacy uncertainty. Reimbursement pushback or slower-than-expected site adoption (outpatient conversion, logistics) are the fastest mechanisms to reverse the current optimism — those would compress realized ASPs and elongate payback periods for adoption economics.

Positioning should express asymmetric upside while capping idiosyncratic downside. Use option structures to capture the H2 2026 data optionality and buy exposure to larger-cap CDMOs as a collateralized way to play volume growth. The consensus is underweighting execution friction (manufacturing bottlenecks, stepwise gross margin improvement) while simultaneously extrapolating best-case market share for earlier-line uptake; either miss creates sharp downside, but a clean in‑vivo readout or smoother scale-up can re-rate LEGN multiple quickly given its current valuation base.

Key Decisions for Investors

• Tactical options: Buy LEGN Jan 2027 25/45 call spread (size 1–2% NAV). Rationale: caps premium paid, preserves upside to a >2x move if in‑vivo data + continued commercial momentum; set max premium risk as stop. Target payoff >2.5x if LEGN >45; downside limited to premium (~100% of allocated risk).
• Idiosyncratic equity + hedge: Buy LEGN stock (1–3% NAV) and short equal-dollar XBI (SPDR S&P Biotech ETF) to isolate idiosyncratic upside through H2 2026. Exit/reevaluate after in‑vivo data release or if LEGN misses two consecutive sales guides; expected reward: asymmetric upside on successful readout, sector-hedged downside.
• Supply-chain play: Overweight Catalent (CTLT) for 6–12 months (target +20–30%, stop -12%). Rationale: incremental fill/finish demand from CAR‑T scale-up benefits CTLT margins and utilization sooner than smaller CDMOs. Size 2–4% NAV.
• Convex hedge: If unwilling to hold LEGN equity, buy LEGN Jan 2027 20–25 delta calls (uncapped) sized small (0.5–1% NAV) to retain existential upside from H2 2026 data while keeping cash exposure low.
• Risk management rule: Trim 30–40% of LEGN directional exposure on a >=50% rally from current levels or if commercial guidance misses two sequential quarters; tighten stops if payer/private insurer policy language becomes unfavorable.